Floatz logo

NADROPARIN

Portal Vein Thrombosis

Shanghai Zhongshan Hospitalother_biologicalPhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Portal Vein Thrombosis cohort.

Asset / SponsorPhaseRating
Sorafenib
First Affiliated Hospital of Zhejiang University
Phase 4BBB
LENVATINIB
First Hospital of China Medical University
Phase 4BBB
WARFARIN
Kafrelsheikh University
Phase 4BB
Enoxaparin
Institute of Liver and Biliary Sciences, India
Phase 4BB
Apixaban
Asian Institute Of Medical Sciences
Phase 4B

View all 27 →

Same molecule, other indications

NADROPARIN is also rated in:

venous thromboembolismDormant
BBB
Indicative ·
75 / 100
View asset →
Esophageal and Gastric VaricesDormant
BB
Indicative ·
69 / 100
View asset →
Anticoagulant-induced BleedingDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →